Patient Derived Vascularized MicroTumor Model of Gastrointestinal Peritoneal Carcinomatosis

NCT ID: NCT05844865

Last Updated: 2025-07-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-05-04

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a pilot study gathering and using samples and data from patients with gastrointestinal peritoneal carcinomatosis. Participants will be asked for permission to provide blood and ascites/peritoneal wash fluid, tumor samples during their planned surgical procedure.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Peritoneal Carcinomatosis Gastrointestinal Peritoneal Carcinomatosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Subjects with Gastrointestinal Primary Tumor with or without Peritoneal Carcinomatosis

Subjects with gastrointestinal (GI) primary tumor with or without peritoneal carcinomatosis who are undergoing planned standard of care (SOC) surgical procedures. Biospecimens such as blood, peritoneal wash fluid and tumor samples will be obtained.

Group Type OTHER

Biospecimen Collection (Blood, Ascites/Peritoneal Wash Fluid and/or Tumor Samples)

Intervention Type OTHER

Subjects with a known diagnosis of GI primary tumor with or without PC, with a planned standard of care surgery.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Biospecimen Collection (Blood, Ascites/Peritoneal Wash Fluid and/or Tumor Samples)

Subjects with a known diagnosis of GI primary tumor with or without PC, with a planned standard of care surgery.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients must have a GI tumor
* Must have planned standard of care surgical procedure
* Age ≥ 18 years.
* Ability to understand and the willingness to sign a written informed consent

Exclusion Criteria

\- Pattens who are unable to comply with the study protocol
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of California, Irvine

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Maheswari Senthil, MD

Professor of Surgery, Division Chief - Surgical Oncology

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Maheswari Senthil, MD FACS

Role: PRINCIPAL_INVESTIGATOR

Chao Family Comprehensive Cancer Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Chao Family Comprehensive Cancer Center, University of California, Irvine

Orange, California, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Chao Family Comprehensive Cancer Center University of California, Irvine

Role: CONTACT

1-877-827-7883

University of California Irvine Medical

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Maheswari Senthil, MD FACS

Role: primary

877-827-8839

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

UCI 22-92

Identifier Type: OTHER

Identifier Source: secondary_id

2214

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Treatment Outcomes of Retroperitoneal Sarcoma
NCT06612671 ACTIVE_NOT_RECRUITING